Skip to content
Review Open access

The gut-brain axis in Alzheimer’s disease: traditional Chinese medicine constituents as modulators of gut-brain homeostasis

Aug 2026 · Frontiers in Microbiology · Vol 17 · 0 citations · 125 references
Medicine

TL;DR

An interesting discrepancy in current findings on SCFAs is addressed: acetate can inhibit inflammation in microglia under mechanical stretch, yet fails to produce the same effect under LPS exposure, Nevertheless, increased SCFA levels in vivo are able to alleviate microglial dysfunction linked to aging.

Abstract

Alzheimer’s disease (AD) currently lacks curative treatments, and the gut–brain axis plays an important role in regulating neuroinflammation during AD progression. Multiple bioactive components from traditional Chinese medicine (TCM), including polysaccharides, alkaloids, flavonoids and saponins, protect neurons through regulating gut microbiota composition, maintaining intestinal barrier function and modulating short-chain fatty acid (SCFA) metabolism. Different from previous reviews that mainly elaborate correlational relationships, the present paper systematically sorts out a multi-level action network of TCM components along the gut-brain axis. We address an interesting discrepancy in current findings on SCFAs: acetate can inhibit inflammation in microglia under mechanical stretch, yet fails to produce the same effect under LPS exposure. Nevertheless, increased SCFA levels in vivo are able to alleviate microglial dysfunction linked to aging. Such findings indicate that SCFA activities are influenced by stimulus types, compound categories and applied doses, reminding researchers to treat existing conclusions with caution. We also outline six widely existing methodological issues in relevant researches, and propose feasible solutions, including the documentation of absolute SCFA concentrations, experimental verification of causal relationships, and the use of AD pathological stimuli like Aβ and tau. This review may facilitate the shift from correlational analysis to mechanistic exploration, and provide useful references for the development of AD therapies targeting the gut–brain axis with TCM components.

Read PDF

Similar papers

Review Sep 2026

The Gut-Brain Axis: Exploring the Role of Gut Microbiota in Alzheimer's Disease Pathogenesis and Therapeutics.

The gut microbiota acts as an upstream regulator of AD pathology through interconnected molecular mechanisms, and microbiota-targeted interventions have the potential to modulate these pathways and improve cognitive outcomes, although results vary across studies.

Javeria Fatima, Y. Siddique · 0 citations
Review Open access Aug 2026

Modulating the Gut‐Microbiota‐Brain Axis in Alzheimer's Disease: Therapeutic Potential of Nutritional and Metabolic Factors

ABSTRACT Background Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia among the elderly, characterized by a gradual decline in memory and cognitive function. The growing body of evidence highlighting the interaction between the gut microbiota and the central nervous...

Bin-Yue Xu, Xu-Huan Li, Shang-Ling Dong et al. · 0 citations
Review Sep 2026

The Gut Microbiota and Gut-Brain Axis in Alzheimer's Disease: From Pathogenesis to Treatment.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder whose pathological course involves amyloid-β (Aβ) deposition, tau abnormalities, neuroinflammation, and neurovascular dysfunction. Interest in the microbiota-gut-brain axis does not arise because gut dysbiosis has been established as an independent in...

Jing-Yi Wang, Lyu Luo, Jiawang Zhang et al. · 0 citations
Review Open access Aug 2026

Research Progress on the Gut–Brain Axis in the Pathogenesis and Progression of Alzheimer’s Disease

Memory impairment and broader cognitive decline emerge gradually in Alzheimer’s disease (AD), although amyloid-β deposition, tau abnormalities, and neuroinflammatory changes often develop well before the clinical picture is fully established. Drug therapy can lessen selected symptoms, but it does not prevent continuing...

Yu-Jie Gao · 0 citations
Open access Aug 2026

Astragalus polysaccharide alleviates neuropathology and cognitive deficits by modulating gut microbiota and neuroinflammation in an Alzheimer’s disease model

Findings demonstrate that APS alleviates cognitive deficits and AD-like pathology, partially through remodeling gut microbiota and modulating the gut-brain axis, and represents a promising natural compound-based therapeutic candidate for managing cognitive decline associated with Alzheimer’s disease.

Xiaolin Cui, Zhen Wei, Qingshui Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.